BioSpace News Archive

People living with type 2 diabetes in the US may not be being prescribed enough blood glucose monitoring (BGM) test strips to help them optimally manage their diabetes, according to new research from Ascensia Diabetes Care, a leading diabetes care company and makers of CONTOUR® NEXT BGM and test strips

Essence SmartCare, a leader in IoT-based remote care solutions, today announced the launch of VitalOn, a comprehensive remote patient monitoring (RPM) platform for active seniors and older adults living with chronic conditions.

--Data demonstrates promise for lead program, ARU-1801, as potentially curative treatment for sickle cell disease--

Individuals with genetic high cholesterol, heart disease or both, who were infected with COVID-19 had more heart attacks according to new research by the FH Foundation.

Escient Pharmaceuticals, Inc. , a clinical-stage, industry-leading platform company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications, today announced that Eric Deng, Ph.D., M.B.A., has joined the company as Vice President, Chemistry, Manufacturing and Controls (CMC) Operations.

PPD, Inc. (Nasdaq: PPD ) has been named “Most Innovative CRO” by North Carolina’s Triangle Business Journal , recognizing the global contract research organization’s strong performance in a year shaped by the COVID-19 pandemic.

Aptevo Therapeutics Inc., a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies announced that the company has initiated the expansion phase of lead anti-leukemia drug candidate, APVO436, in adult patients with acute myeloid leukemia with a multi-center, multi-arm trial using the active recommended dose identified in the dose escalation phase of the study.

NAFLD Fibrosis Score (NFS) was developed to predict the presence of significant fibrosis using common clinical and laboratory values

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Gelesis, announced today a poster presentation at the American Association of Clinical Endocrinology (AACE) 2021 Annual Virtual Meeting

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks.